ES2105868T3 - Derivados antitromboticos de amidinofenilalanina y amidinopiridilalanina. - Google Patents

Derivados antitromboticos de amidinofenilalanina y amidinopiridilalanina.

Info

Publication number
ES2105868T3
ES2105868T3 ES95900087T ES95900087T ES2105868T3 ES 2105868 T3 ES2105868 T3 ES 2105868T3 ES 95900087 T ES95900087 T ES 95900087T ES 95900087 T ES95900087 T ES 95900087T ES 2105868 T3 ES2105868 T3 ES 2105868T3
Authority
ES
Spain
Prior art keywords
conr5r6
pct
optionally substituted
alkyl
nr5r6
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95900087T
Other languages
English (en)
Inventor
John Christopher Pf Danilewicz
David Ellis
Ryszard Jurek Kobylecki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Research and Development Co NV SA
Original Assignee
Pfizer Research and Development Co NV SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Research and Development Co NV SA filed Critical Pfizer Research and Development Co NV SA
Application granted granted Critical
Publication of ES2105868T3 publication Critical patent/ES2105868T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Treating Waste Gases (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

LOS COMPUESTOS DE LA FORMULA (I), LA SAL FARMACEUTICAMENTE ACEPTABLE DE LOS MISMOS Y LOS SOLVATOS FARMACEUTICAMENTE ACEPTABLES DE CUALQUIERA DE LOS DOS, EN DONDE X ES CH O N; Y ES ALQUILENO C{SUB,3}-C{SUB,5} OPCIONALMENTE MONOINSATURADO OPCIONALMENTE SUSTITUIDO POR ALQUILO C{SUB,1}-C{SUB,4} O METILENO; R{SUP,1} ES H; ALQUILO C{SUB,1}-C{SUB,4} OPCIONALMENTE SUSTITUIDO POR ALCOXI C{SUB,1}-C{SUB,4}, OH, NR{SUP,5}R{SUP,6}, CONR{SUP,5}R{SUP,6}, CICLOALQUILO C{SUB,3}-C{SUB,6} O ARILO; O ALQUENILO C{SUB,3}-C{SUB,6}; R{SUP,2} ES H; ALQUILO C{SUB,1}C{SUB,4} OPCIONALMENTE SUSTITUIDO POR ALCOXI C{SUB,1}-C{SUB,4}, OH, NR{SUP,5}R{SUP,6}, CONR{SUP,5}R{SUP,6}, CICLOALQUILO C{SUB,3}-C{SUB,6} O ARILO; O CONR{SUP,5}R{SUP,6}; R{SUP,3} Y R{SUP,4} SE SELECCIONAN CADA UNO, INDEPENDIENTEMENTE, DEL H; ALQUILO C{SUB,1}-C{SUB,4} OPCIONALMENTE SUSTITUIDO POR NR{SUP,5}R{SUP,6}; ALCOXI C{SUB,1}-C{SUB,4}; HALO; CONR{SUP,5}R{SUP,6} Y ARILO; R{SUP,5} Y R{SUP,6} SE SELECCIONAN CADA UNO, INDEPENDIENTEMENTE, DEL H Y ALQUILOC{SUB,1}-C{SUB,4}; Y M Y N SON CADA UNA, INDEPENDIENTEMENTE, 1, 2 O 3; SON INHIBIDORES POTENTES Y SELECTIVOS DE LA TROMBINA UTILES EN EL TRATAMIENTO DE, ENTRE OTRAS, LA TROMBOSIS VENOSA PROFUNDA; REOCLUSION TRAS UNA TERAPIA TROMBOLITICA; OBSTRUCCION ARTERIAL CRONICA; ENFERMEDAD VASCULAR PERIFERICA; INFARTO DE MIOCARDIO AGUDO; ANGINA INESTABLE; FIBRILACION AURICULAR; ATAQUE TROMBOTICO; ATAQUES ISQUEMICOS PASAJEROS; RESTENOSIS Y OCLUSION TRAS UNA ANGIOPLASTIA; O TRASTORNOS NEURODEGENERATIVOS.
ES95900087T 1993-11-08 1994-10-24 Derivados antitromboticos de amidinofenilalanina y amidinopiridilalanina. Expired - Lifetime ES2105868T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939322976A GB9322976D0 (en) 1993-11-08 1993-11-08 Therapeutic agents

Publications (1)

Publication Number Publication Date
ES2105868T3 true ES2105868T3 (es) 1997-10-16

Family

ID=10744811

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95900087T Expired - Lifetime ES2105868T3 (es) 1993-11-08 1994-10-24 Derivados antitromboticos de amidinofenilalanina y amidinopiridilalanina.

Country Status (25)

Country Link
US (2) US5750520A (es)
EP (1) EP0728132B1 (es)
JP (1) JP2739776B2 (es)
KR (1) KR960705807A (es)
CN (1) CN1134148A (es)
AT (1) ATE155464T1 (es)
AU (1) AU680565B2 (es)
CA (1) CA2176037C (es)
CO (1) CO4290420A1 (es)
CZ (1) CZ282359B6 (es)
DE (1) DE69404325T2 (es)
DK (1) DK0728132T3 (es)
ES (1) ES2105868T3 (es)
FI (1) FI112481B (es)
GB (1) GB9322976D0 (es)
GR (1) GR3024228T3 (es)
HU (1) HUT76268A (es)
IL (1) IL111478A0 (es)
NO (1) NO961841L (es)
NZ (1) NZ275798A (es)
PE (1) PE22795A1 (es)
PL (1) PL314237A1 (es)
SG (1) SG52218A1 (es)
WO (1) WO1995013274A1 (es)
ZA (1) ZA948772B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9522495D0 (en) * 1995-11-02 1996-01-03 Pfizer Ltd Therapeutic agents
US7109326B2 (en) 1997-04-15 2006-09-19 Genentech, Inc. Halo-alkoxycarbonyl prodrugs
IL123986A (en) 1997-04-24 2011-10-31 Organon Nv Medicinal compounds
US6740682B2 (en) 1997-08-29 2004-05-25 Tularik Limited Meta-benzamidine derivatives as serine protease inhibitors
AU8875798A (en) * 1997-08-29 1999-03-22 Proteus Molecular Design Ltd Meta-benzamidine derivatives as serin protease inhibitors
AU9512298A (en) * 1997-09-30 1999-04-23 Molecular Design International, Inc. Beta3-adrenoreceptor agonists, agonist compositions and methods of using
DK0997474T3 (da) 1998-08-14 2004-02-09 Pfizer Antithrombotiske midler
AU2001256733A1 (en) * 2000-05-16 2001-11-26 Takeda Chemical Industries Ltd. Melanin-concentrating hormone antagonist
SI20743A (sl) 2000-12-22 2002-06-30 Univerza V Ljubljani, Novi trombinski inhibitorji
US6593341B2 (en) 2001-03-29 2003-07-15 Molecular Design International, Inc. β3-adrenoreceptor agonists, agonist compositions and methods of making and using the same
SI21137A (sl) * 2002-01-24 2003-08-31 LEK, tovarna farmacevtskih in kemičnih izdelkov, d.d. Derivati azafenilalanina
US6953787B2 (en) * 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators
CN1703395A (zh) * 2002-08-09 2005-11-30 特兰斯泰克制药公司 芳基和杂芳基化合物以及调节凝血的方法
US6596734B1 (en) 2002-10-11 2003-07-22 Molecular Design International, Inc. Tetrahydroisoquinoline compounds for use as β3-adrenoreceptor agonists
CN101792417A (zh) 2003-06-17 2010-08-04 艾尼纳制药公司 用于治疗5ht2c受体相关疾病的苯并氮杂卓衍生物
MXPA05013364A (es) 2003-06-17 2006-03-17 Arena Pharm Inc Procedimiento para preparar 3-benzazepinas.
JP2007501844A (ja) * 2003-08-08 2007-02-01 トランス　テック　ファーマ，インコーポレイテッド アリール及びヘテロアリール化合物、組成物並びに使用方法
US7208601B2 (en) * 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
US7459472B2 (en) * 2003-08-08 2008-12-02 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
WO2005042490A1 (en) * 2003-10-22 2005-05-12 Arena Pharmaceuticals, Inc. Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases
WO2005042491A1 (en) * 2003-10-22 2005-05-12 Arena Pharmaceuticals, Inc. Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases
SI1838677T1 (sl) 2004-12-21 2010-01-29 Arena Pharm Inc Kristalne oblike (R)-8-kloro-1-metil-2,3,4,5-tetrahidro-1H-3-benzazepin hidroklorida
EA015012B1 (ru) 2004-12-23 2011-04-29 Арена Фармасьютикалз, Инк. Композиция, содержащая фентермин и избирательный агонист рецептора 5ht, и ее применение
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0523539D0 (en) * 2005-11-18 2005-12-28 Lek Tovarna Farmacevtskih New use of organic compounds
SG10201508066VA (en) 2006-04-03 2015-10-29 Arena Pharm Inc Processes for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates related thereto
TWI389899B (zh) * 2006-08-08 2013-03-21 Msd Oss Bv 具口服活性之凝血酶抑制劑
ES2522587T3 (es) 2006-12-05 2014-11-17 Arena Pharmaceuticals, Inc. Procesos para preparar (R)-8-cloro-1-metil-2,3,4,5-tetrahidro-1H-3-benzacepina e intermedios de la misma
CA2714654A1 (en) * 2008-02-21 2009-08-27 Sanofi-Aventis Chlorothiophene-amides as inhibitors of coagulation factors xa and thrombin
WO2009103439A1 (en) * 2008-02-21 2009-08-27 Sanofi-Aventis Chlorothiophene-isoxazoles as inhibitors of coagulation factors xa and thrombin
WO2009111004A1 (en) * 2008-03-04 2009-09-11 Arena Pharmaceuticals, Inc. Processes for the preparation of intermediates related to the 5-ht2c agonist (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine
EP2443080A2 (en) 2009-06-18 2012-04-25 Arena Pharmaceuticals, Inc. Process for the preparation of 5-ht2c receptor agonists
AR080375A1 (es) 2010-03-05 2012-04-04 Sanofi Aventis Procedimiento para la preparacion de 2-(cicloheximetil)-n-{2-[(2s)-1-metilpirrolidin-2-il] etil}-1,2,3,4-tetrahidroisoquinolina- 7-sulfonamida
WO2011153206A1 (en) 2010-06-02 2011-12-08 Arena Pharmaceuticals, Inc. Processes for the preparation of 5-ht2c receptor agonists
KR20180118801A (ko) 2010-09-01 2018-10-31 에자이 알앤드디 매니지먼트 가부시키가이샤 체중 관리에 유용한 5-ｈｔ2ｃ 작동제의 변형-방출 투여 형태
EP2611433A2 (en) 2010-09-01 2013-07-10 Arena Pharmaceuticals, Inc. Non-hygroscopic salts of 5-ht2c agonists
SG188365A1 (en) 2010-09-01 2013-04-30 Arena Pharm Inc Administration of lorcaserin to individuals with renal impairment
EP2611782A1 (en) 2010-09-01 2013-07-10 Arena Pharmaceuticals, Inc. Salts of lorcaserin with optically active acids
KR20190128001A (ko) 2012-10-09 2019-11-13 에자이 알앤드디 매니지먼트 가부시키가이샤 체중 관리 방법
US10968172B2 (en) 2017-05-15 2021-04-06 Mitobridge, Inc. USP30 inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8868991A (en) * 1990-11-15 1992-06-11 Pentapharm Ag Meta-substituted phenyl alanine derivatives

Also Published As

Publication number Publication date
CZ282359B6 (cs) 1997-07-16
PE22795A1 (es) 1995-08-15
EP0728132A1 (en) 1996-08-28
JP2739776B2 (ja) 1998-04-15
DE69404325D1 (de) 1997-08-21
DK0728132T3 (da) 1997-09-01
GR3024228T3 (en) 1997-10-31
FI112481B (fi) 2003-12-15
FI961939A (fi) 1996-05-07
KR960705807A (ko) 1996-11-08
AU680565B2 (en) 1997-07-31
US5750520A (en) 1998-05-12
GB9322976D0 (en) 1994-01-05
NO961841D0 (no) 1996-05-07
CA2176037C (en) 1999-07-13
FI961939A0 (fi) 1996-05-07
ATE155464T1 (de) 1997-08-15
CA2176037A1 (en) 1995-05-18
US5861393A (en) 1999-01-19
SG52218A1 (en) 1998-09-28
HU9601229D0 (en) 1996-07-29
IL111478A0 (en) 1994-12-29
CZ132296A3 (en) 1996-08-14
PL314237A1 (en) 1996-09-02
CO4290420A1 (es) 1996-04-17
ZA948772B (en) 1996-05-07
CN1134148A (zh) 1996-10-23
JPH09500391A (ja) 1997-01-14
DE69404325T2 (de) 1997-10-30
WO1995013274A1 (en) 1995-05-18
HUT76268A (en) 1997-07-28
EP0728132B1 (en) 1997-07-16
NO961841L (no) 1996-05-07
NZ275798A (en) 1997-09-22
AU8104994A (en) 1995-05-29

Similar Documents

Publication Publication Date Title
ES2105868T3 (es) Derivados antitromboticos de amidinofenilalanina y amidinopiridilalanina.
GR3033070T3 (en) Antithrombotic amidinotetrahydropyridylalanine derivatives
DE60221391D1 (de) Substituierte indolsäurederivate als inhibitoren von plasminogen-aktivator-inhibitor-1 (pai-1)
EA200100411A1 (ru) Замещенные 3-цианохинолины в качестве ингибиторов протеинтирозинкиназ
EA200100412A1 (ru) Замещенные 3-цианохинолины в качестве ингибиторов протеинтирозинкиназ
ATE331708T1 (de) Substituierte 3-alkyl- und 3-arylalkyl-1h-indol-1-yl-essigsäure-derivate als plasminogen aktivator inhibitor-1 (pai-1) inhibitoren
DK1569901T3 (da) Aryl-, aryloxy- og alkoxysubstituerede 1H-indol-3-yl-glyoxylsyrederivater som inhibitorer af plasminogenaktivatorinhibitor-1 (PAI-1)
WO2004052893A3 (en) Substituted dihydropyrano indole-3,4-dione derivatives and 3-oxoacetic acid substituted 2-hydroxymethylindole derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
MXPA03011400A (es) Derivados de naftil benzofurano como inhibidores del inhibidor-1de activador de plasminogeno (pai-1).
NO20010203L (no) Diacylhydrazinderivater som integrininhibitorer
SE9804313D0 (sv) New compounds
MX9708278A (es) Derivados de amidinotetrahidropiridilalanina, procedimiento para su preparacion y uso de los mismos.
MX9803498A (es) Derivados de n-amidino piperidina y benzamidina antitromboticos.
RS20050514A (en) Compounds having prolyl oligopeptidase inhibitory activity
EA200300059A1 (ru) Комбинированная противоопухолевая терапия, включающая применение производных замещенного акрилоилдистамицина, таксанов и/или антиметаболитов
ECSP961723A (es) Derivados de amidinotetrahidropiridilalanina antitromboticos
KR950700897A (ko) 옥소-및 히드록시-치환된 탄화수소의 아민 유도체(Amine Derivatives of oxo- and hydroxy-substituted hydrocarbons)

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 728132

Country of ref document: ES